My watch list
my.bionity.com  
Login  

Evotec and Celmatix enter into strategic collaboration

10-Oct-2019

Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility.

The pairing of the capabilities of Evotec and Celmatix has the potential to impact the lives of millions of women living with these reproductive health conditions by bringing long overdue innovation in the form of therapies with novel mechanisms of action. In this research collaboration, Evotec will be responsible for medicinal chemistry, in vitro and in vivo pharmacology, in addition to its broad development capabilities and expertise, while Celmatix will contribute novel drug target discovery, powered by its proprietary multi-omics Reproductive Atlas™ platform.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are delighted to partner with Celmatix on this initiative. At Evotec we focus on patient-centric approaches and leveraging human genetic and big data into women’s health specific drug discovery is long overdue. We are convinced that our combined efforts will lead to highly innovative approaches with the potential to broadly impact women-focused unmet medical needs.”

“Reproductive health conditions collectively impact over 30% of women around the world and set the stage for later conditions such as cardiovascular disease and metabolic disorders. Endometriosis alone is estimated to cost the US economy over $78 billion annually, and available medical interventions have only limited utility. It’s time to move beyond the incremental improvements we have seen in the standard of care for these conditions and bring true innovation to the field.” said Dr Piraye Yurttas Beim, CEO and founder of Celmatix. “Through combining our vast datasets and deep expertise in women’s health with Evotec’s proven experience in therapeutic discovery, we are poised to catalyse real change and finally provide women therapies they deserve.”

No financial terms of this collaboration were disclosed.

Facts, background information, dossiers
More about Evotec
  • News

    Evotec and Vifor Pharma form joint venture

    Evotec SE and Vifor Pharma announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology therapeutics. Vifor Pharma will be benefiting from access to an external R&D capability for the development of its own nephrology pipeline, while Evotec will ... more

    Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian

    Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. Aeovian and Evotec entered into a drug discovery partnership in 2017 to discover and develop new and highly selective ... more

    Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration

    Evotec SE and Indivumed GmbH announced that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer. Under the terms of the collaboration agreement, Evotec received full access to the colorect ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE